Spinal cord injury sequelae alter drug pharmacokinetics: An overview

Spinal Cord

Volumn 49, Issue 9, 2011, Pages 955-960

  Mestre, H ^a   Alkon, T ^a   Salazar, S ^a   Ibarra, A ^a  

^a UNIVERSIDAD ANÁHUAC   (Mexico)

Author keywords

autonomic dysreflexia; paraplegia; pathophysiology; pharmacokinetics; pharmacotherapy

Indexed keywords

4 AMINOPYRIDINE; ACETYLSALICYLIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTIBIOTIC AGENT; ARGININE; BACLOFEN; CARBAMAZEPINE; CEFOTIAM; CIPROFLOXACIN; CYCLOSPORIN A; DANTROLENE; DIAZEPAM; DICLOFENAC; DOXYCYCLINE; GENTAMICIN; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; KETAMINE; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; MUSCLE RELAXANT AGENT; NAPROXEN; PARACETAMOL; PHENACETIN; THEOPHYLLINE; UNINDEXED DRUG; VANCOMYCIN;

AREFLEXIA; ATELECTASIS; BRADYCARDIA; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DETRUSOR DYSSYNERGIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG TRANSFORMATION; DYSPEPSIA; FLACCID PARALYSIS; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; HYPERREFLEXIA; HYPOTENSION; KIDNEY FAILURE; LUNG EDEMA; MEDLINE; MUSCLE HYPERTONIA; MUSCLE SPASM; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OVERACTIVE BLADDER; PARAMETER; PHARMACOKINETICS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SPASTICITY; SPINAL CORD INJURY; SYSTEMATIC REVIEW;

ANALGESICS; ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METABOLIC DETOXICATION, DRUG; NEUROMUSCULAR AGENTS; SPINAL CORD INJURIES;

EID: 80052393320     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2011.58     Document Type: Review

References (54)

1. Privat A. Pathophysiology and treatment of spinal cord injury. Bull Acad Natl Med 2005; 189: 1109-1117.
2. Bravo G, Guizar-Sahagun G, Ibarra A, Centurion D, Villalon CM. Cardiovascular alterations after spinal cord injury: an overview. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 133-148. (Pubitemid 38854975)
3. van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J. Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology 2010; 34: 184-192.
4. Shavelle RM, DeVivo MJ, Paculdo DR, Vogel LC, Strauss DJ. Long-term survival after childhood spinal cord injury. J Spinal Cord Med 2007; 30(Suppl 1): S48-S54. (Pubitemid 47320252)
5. Berkowitz M. The costs of spinal cord injury. In: Lin VW, Cardenas DD, Cutter NC, et al. (eds). Spinal Cord Medicine: Principles and Practice. Demos Medical Publishing: New York, 2003.
6. Segal JL, Brunnemann SR, Gray DR. Gentamicin bioavailability and single-dose pharmacokinetics in spinal cord injury. Drug Intell Clin Pharm 1988; 22: 461-465.
7. Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 773-777. (Pubitemid 24214953)
8. Qin W, Bauman WA, Cardozo C. Bone and muscle loss after spinal cord injury: organ interactions. Ann N Y Acad Sci 2010; 1211: 66-84.
9. Mathias CJ, Naik RB, Warren DJ, Frankel HL. Autonomic neuropathy. Arch Intern Med 1983; 143: 1635.
10. Garstang SV, Miller-Smith SA. Autonomic nervous system dysfunction after spinal cord injury. Phys Med Rehabil Clin N Am 2007; 18: 275-296. (Pubitemid 46818027)
11. Guizar-Sahagun G, Velasco-Hernandez L, Martinez-Cruz A, Castaneda-Hernandez G, Bravo G, Rojas G et al. Systemic microcirculation after complete high and low thoracic spinal cord section in rats. J Neurotrauma 2004; 21: 1614-1623. (Pubitemid 39525170)
12. Stevens RD, Bhardwaj A, Kirsch JR, Mirski MA. Critical care and perioperative management in traumatic spinal cord injury. J Neurosurg Anesthesiol 2003; 15: 215-229. (Pubitemid 36807884)
13. Bolser DC, Jefferson SC, Rose MJ, Tester NJ, Reier PJ, Fuller DD et al. Recovery of airway protective behaviors after spinal cord injury. Respir Physiol Neurobiol 2009; 169: 150-156.
14. Lu CL, Montgomery P, Zou X, Orr WC, Chen JD. Gastric myoelectrical activity in patients with cervical spinal cord injury. Am J Gastroenterol 1998; 93: 2391-2396. (Pubitemid 29018544)
15. Enck P, Klosterhalfen S. Placebo response in functional bowel disorders. Z Gastroenterol 2006; 44: 257-266.
16. Longo WE, Ballantyne GH, Modlin IM. The colon, anorectum, and spinal cord patient. A review of the functional alterations of the denervated hindgut. Dis Colon Rectum 1989; 32: 261-267.
17. Preziosi G, Emmanuel A. Neurogenic bowel dysfunction: patho-physiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 2009; 3: 417-423.
18. Silver JR, Doggart JR. Reduced sodium output following acute spinal injury. Spinal Cord 2004; 42: 191-198. (Pubitemid 38406577)
19. Chen Y, DeVivo MJ, Stover SL, Lloyd LK. Recurrent kidney stone: a 25-year follow-up study in persons with spinal cord injury. Urology 2002; 60: 228-232. (Pubitemid 34831763)
20. Birder LA, de Groat WC. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol 2007; 4: 46-54. (Pubitemid 46062986)
21. Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, Aoki KR et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int 2008; 52: 1068-1075.
22. de Groat WC, Kawatani M, Hisamitsu T, Cheng CL, Ma CP, Thor K et al. Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 1990; 30(Suppl): S71-S77. (Pubitemid 20244728)
23. Rodriguez GP, Claus-Walker J, Kent MC, Garza HM. Collagen metabolite excretion as a predictor of bone-and skin-related complications in spinal cord injury. Arch Phys Med Rehabil 1989; 70: 442-444. (Pubitemid 19158869)
24. Rodriguez GP, Claus-Walker J, Kent MC, Stal S. Adrenergic receptors in insensitive skin of spinal cord injured patients. Arch Phys Med Rehabil 1986; 67: 177-180. (Pubitemid 16016324)
25. Fuentes-Lara G, Guizar-Sahagun G, Garcia-Lopez P. Effect of experimental spinal cord injury on salicylate bioavailability after oral aspirin administration. J Pharmacol Toxicol Methods 1999; 42: 93-97. (Pubitemid 30618981)
26. Segal JL, Brunnemann SR, Gordon SK, Eltorai IM. The absolute bioavailability of oral theophylline in patients with spinal cord injury. Pharmacotherapy 1986; 6: 26-29. (Pubitemid 16103458)
27. Gilman TM, Segal JL, Brunnemann SR. Metoclopramide increases the bioavailability of dantrolene in spinal cord injury. J Clin Pharmacol 1996; 36: 64-71. (Pubitemid 26058812)
28. Reihani-Kermani H, Ansari M, Karamousian S. The influence of experimental spinal cord injury on carbamazepine pharmacoki-netics. Arch Iran Med 2006; 9: 231-235. (Pubitemid 44122233)
29. Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004; 85: 29-34. (Pubitemid 38049587)
30. Ibarra A, Guizar-Sahagun G, Correa D, Kretschmer R, Grijalva I, Flores-Murrieta FJ et al. Alteration of cyclosporin-A pharmacoki-netics after experimental spinal cord injury. J Neurotrauma 1996; 13: 267-272. (Pubitemid 26192774)
31. Aisen ML, Dietz MA, Rossi P, Cedarbaum JM, Kutt H. Clinical and pharmacokinetic aspects of high dose oral baclofen therapy. J Am Paraplegia Soc 1992; 15: 211-216.
32. Schulz-Stubner S. The use of small-dose theophylline for the treatment of bradycardia in patients with spinal cord injury. Anesth Analg 2005; 101: 1809-1811. (Pubitemid 41720641)
33. Nantwi KD, Goshgarian HG. Effects of chronic systemic theo-phylline injections on recovery of hemidiaphragmatic function after cervical spinal cord injury in adult rats. Brain Res 1998; 789: 126-129. (Pubitemid 28206852)
34. Aslan A, Cemek M, Buyukokuroglu ME, Altunbas K, Bas O, Yurumez Y et al. Dantrolene can reduce secondary damage after spinal cord injury. Eur Spine J 2009; 18: 1442-1451.
35. Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opin Pharmacother 2002; 3: 1411-1420. (Pubitemid 35174873)
36. Sirlak M, Eryilmaz S, Bahadir IM, Sirin YS, Besalti O, Yazicioglu L et al. Effects of carbamazepine on spinal cord ischemia. J Thorac Cardiovasc Surg 2008; 136: 1038-1043.
37. Cardenas DD, Ditunno J, Graziani V, Jackson AB, Lammertse D, Potter P et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord 2007; 45: 158-168. (Pubitemid 46204264)
38. Ibarra A, Diaz-Ruiz A. Protective effect of cyclosporin-A in spinal cord injury: an overview. CurrMed Chem 2006; 13: 2703-2710. (Pubitemid 44364147)
39. Nimmo J, Heading RC, Tothill P, Prescott LF. Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption. Br Med J 1973; 1: 587-589.
40. Segal JL, Brunnemann SR. Clinical pharmacokinetics in patients with spinal cord injuries. Clin Pharmacokinet 1989; 17: 109-129. (Pubitemid 19199636)
41. Garcia-Lopez P, Salas R. Bioavailability of diclofenac after intramuscular administration to rats with experimental spinal cord injury. JPharmacol Toxicol Methods 1999; 42: 99-101. (Pubitemid 30618982)
42. Buxton, ILO. Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In: Brunton LL, Lazo JS and Parker KL (eds) Goodman & Gilmańs The Pharmacological Basis of Therapeutics, 11th edn. MacGraw-Hill: Iowa, 2006. http://www.accessmedicine.com/ features.aspx.
43. Garcia-Lopez P, Martinez-Cruz A, Guizar-Sahagun G, Castaneda-Hernandez G. Acute spinal cord injury changes the disposition of some, but not all drugs given intravenously. Spinal Cord 2007; 45: 603-608. (Pubitemid 47373815)
44. Segal JL, Gonzales E, Yousefi S, Jamshidipour L, Brunnemann SR. Circulating levels of IL-2R, ICAM-1, and IL-6 in spinal cord injuries. Arch Phys Med Rehabil 1997; 78: 44-47. (Pubitemid 27034243)
45. Katz J, Bonorris G, Sellers AL. Extravascular albumin in human tissues. Clin Sci 1970; 39: 725-729.
46. Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth 2003; 90: 155-160. (Pubitemid 36181958)
47. Segal JL, Brunnemann SR, Eltorai IM, Vulpe M. Decreased systemic clearance of lorazepam in humans with spinal cord injury. J Clin Pharmacol 1991; 31: 651-656.
48. Segal, JL, Brunnemann, SR, Castañeda-Hernández, G, Guizar-Sahagún, G. Altered hepatocyte gene expression in a rat model of chronic spinal cord injury. J Clin Pharmacol 2000; 40: 1045-1065.
49. Segal JL, Maltby BF, Langdorf MI, Jacobson R, Brunnemann SR, Jusko WJ. Methylprednisolone disposition kinetics in patients with acute spinal cord injury. Pharmacotherapy 1998; 18: 16-22. (Pubitemid 28058998)
50. Vertiz-Hernandez A, Castaneda-Hernandez G, Martinez-Cruz A, Cruz-Antonio L, Grijalva I, Guizar-Sahagun G. L-arginine reverses alterations in drug disposition induced by spinal cord injury by increasing hepatic blood flow. J Neurotrauma 2007; 24: 1855-1862.
51. Lavezo LA, Davis RL. Vancomycin pharmacokinetics in spinal cord injured patients: a comparison with age-matched, able-bodied controls. J Spinal Cord Med 1995; 18: 233-235.
52. Brunnemann SR, Segal JL. Amikacin serum protein binding in spinal cord injury. Life Sci 1991; 49: L1-L5.
53. Dahlin PA, George J. Baclofen toxicity associated with declining renal clearance after ibuprofen. Drug Intell Clin Pharm 1984; 18: 805-808. (Pubitemid 14038855)
54. Pedersen SS, Hørbov S, Biering-Sørensen F, Høiby N. Peroral treatment with ciprofloxacin of patients with spinal cord lesion and bacteriuria caused by multiply resistant bacteria. Paraplegia 1990; 28: 41-47. (Pubitemid 20078478)